Serpins in Hemostasis as Therapeutic Targets for Bleeding or Thrombotic Disorders

Bleeding and thrombotic disorders result from imbalances in coagulation or fibrinolysis, respectively. Inhibitors from the serine protease inhibitor (serpin) family have a key role in regulating these physiological events, and thus stand out as potential therapeutic targets for modulating fibrin clot formation or dismantling. Here, we review the diversity of serpin-targeting strategies in the area of hemostasis, and detail the suggested use of modified serpins and serpin inhibitors (ranging from small-molecule drugs to antibodies) to treat or prevent bleeding or thrombosis.

Automated summary

Disorders related to bleeding and thrombosis are caused by imbalances in coagulation or fibrinolysis. Inhibitors from the serpin family play a crucial role in regulating these physiological events and are considered as potential therapeutic targets. The review discusses various serpin-targeting strategies in hemostasis and suggests the use of modified serpins and inhibitors for treating or preventing bleeding or thrombosis.